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Studies about the role of cytokines on the immunopathogenesis of atopic dermatitis (AD) are generally based on in vitro observa-
tions and this role has not been completely clariﬁed yet. Serum levels of total IgE, IL-18, IL-12, IFN-γ and the relationship between
these parameters and disease severity, determined using the SCORAD index, in a group of atopic patients were investigated in
this study. Serum levels of total IgE were measured by the nephelometric method and serum levels of IL-18, IL-12/p40 and IFN-
γ were measured by ELISA method. Serum levels of total IgE and IL-18 were found signiﬁcantly higher in study group than in
controls (P<. 001). There was no statistically signiﬁcant diﬀerence between patients and controls in respect of serum levels of IL-
12/p40 (P = .227). A statistically signiﬁcant relationship between SCORAD values and serum levels of total IgE (P<. 001), IL-18
(P<. 001), and IL-12/p40 (P<. 001) was determined. These results show that serum levels of IL-18 can be a sensitive parameter
that importantly correlates with clinical severity of AD, can play a role in the immunopathogenesis of AD, and furthermore may
be used in the diagnosis and follow-up of the disease in addition to other parameters.
Copyright © 2006 Murat Aral et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Atopic dermatitis (AD) is a frequently encountered, chronic,
severely itchy, eczematous, and inﬂammatory skin disease
that can seriously aﬀect health quality. Encounter frequency
ofthisdiseaseisincreasinggraduallyandthelatestdataabout
the immunopathogenesis of the disease have led to the devel-
opment of new eﬀective treatment models [1–3].
Many patients with AD (80–90%) have high serum levels
of IgE [4]. When IgE binds to the surface antigens of mast
cells, mast cells degranulate and the released mediators cause
dermatitis to be formed. It is determined in recent times that
IgE causes IL-1, IL-3, IL-4, IL-5, IL-6, GM-CSF, and TNF-α
to be synthesized and released by binding to basophils and
mast cells. These cytokines play an important role in the late
p h a s eo fa l l e r g i cr e s p o n s e[ 5]. Local cytokine proﬁle is a crit-
ical determinant of AD skin lesions [6]. TNF-α, one of these
cytokines, inhibits the growth of Th1 cells and this can cause
immune order to spoil. Most of the lymphocytes in the skin
with AD secrete Th2 cytokines and IL-10, IL-4, IL-13 [7].
Expression of GM-CSF mRNA and IL-12/p40 subunits is in-
creasedinchronicatopicdermatitisskinlesionscomparedto
normal skin [8]. These cytokine proﬁles require a Th2 dom-
inant environment in the continuity of AD lesions. Besides,
IL-4andIL-13induceIgEproductionbyIgheavychainregu-
lation and reduce lymphocyte and eosinophil production by
VCAM-1 increase [9]. These ﬁndings correlate with clinical
signs of AD [10].
IL-18 is a recently deﬁned member of IL-1 cytokine fam-
ily and was known as IFN-γ stimulating factor before. Later
studies put forward that it has wide range eﬀects other than
lymphocyte activation. So, it is understood that IL-18 is an
important regulator in the production of both innate and ac-
quired immune responses [11, 12]. IL-18 directly regulates
the eﬀects of T and B cells, NK cells, macrophages, dendritic
cells (DC), and condrocytes [13]. Progression of type-1 lym-
phocyte and NK cell responses occurs basically by synergic
participation of IL-12. But this synergism is probably spe-
ciﬁcbecausetype-2responsecanbeformedbyIL-18without
IL-12 existence [11, 12, 14]. In addition to this, wide range2 Mediators of Inﬂammation
eﬀects of IL-18 on functions of macrophages and dendritic
cells occur directly independent from IFN-γ or indirectly by
the mediation of cytokines produced by T cells and NK cells.
IL-18 can also induce production of IgE and Th2 cytokines
assynergisticallywithIL-2[15,16].Wecanseereverseeﬀects
of IL-18 like being able to crossregulate Th1/Th2 derivation
also in IL-12 [17–19].
Studiesabouttheroleofcytokinesonformationofatopic
diseases are rather new and most of them are based on in
vitro observations. It is not completely clear yet how cy-
tokines regulate diseases in vivo and studies about this sub-
ject are rather limited. Furthermore, the severity of AD is
based on clinical observations and there is no objective lab-
oratory parameter to assess the severity. Serum levels of total
IgE, IL-18, IL-12, IFN-γ and the relationship between these
parameters and the disease severity in a group of child pa-
tients with AD were investigated in this study.
MATERIAL AND METHODS
Patients
Twenty consecutive child patients with AD who applied to
dermatology clinic of KSU (5–12 year old; 11 males, 9 fe-
males) were included in this study as study group and 19 vol-
unteers who have no dermatologic or systemic disease and
were in accordance with study group in respect of age (5–
11 year old; 10 males, 9 females) were included in this study
as control group. AD patients were determined according to
Haniﬁn and Rajka criteria [20]. Disease history was taken
from patients or their parents. Patients who received ultra-
violet therapy or immunotherapy before, who received local
or systemic therapy in last 3 weeks, or who have any other
systemic, allergic, parasitic, or dermatologic disease were ex-
cluded from this study.
Assessmentofdiseaseseverity
The severity of AD was assessed by the same dermatologist
using the Scoring Atopic Dermatitis (SCORAD) index sys-
tem [21].
MeasuringserumlevelsoftotalIgEandcytokines
Blood samples taken from AD patients (study group) and
healthy individuals (control group) were kept at room tem-
perature for 30 minutes till they coagulate. Then they were
centrifuged at 2000rpm for 10 minutes and serums were ob-
tained. These serums were preserved at −70◦C and dissolved
just before the analysis. Total IgE levels were measured by
the nephelometric method (Dade Behring Marburg GmbH,
Marburg, Germany). IL-18, IL-12 (by IL-12 p40 kit), and
IFN-γ levels were measured by ELISA method (BioSource
Europe SA, 8 B-1400 Nivelles, Belgium). The minimal detec-
tion levels of cytokines using these methods were 12.5pg/mL
forIL-18(inter-andintra-assayreproducibilitieswere%8.54
and %4.93); <4pg/mL for IFN-γ (inter- and intra-assay pre-
cisions were %6.0 and %5.2) and <2pg/mLforIL-12p40
subunit (inter- and intra-assay precisions were %3.9 and
%3.9).
Statisticalanalysis
All variables were expressed as mean values ± SD, me-
dian, and range. Undetected cytokine levels were set at the
minimum detectable concentrations. Nonparametric statis-
tical methods were applied to continuous variables. Mann-
Whitney U test and Spearman’s nonparametric correlation
test wereused forstatistical analysis.P values <. 05 were con-
sidered statistically signiﬁcant. Analyses were performed by
using SPSS software, version 11.0 for Windows (SPSS Inc,
Chicago, Il).
RESULTS
The SCORAD values were found between 3 and 35 (mean ±
SD: 12±7) in the patients. Serum total IgE levels were statis-
tically signiﬁcantly higher in study group (176–847IU/mL)
than in control group (18–81IU/mL) (P<. 001). Serum lev-
elsofIL-18weredeterminedinallpatientsinthestudygroup
but could be determined in only 19 of healthy individuals
in the control group. Serum levels of IL-18 were determined
statistically and were found signiﬁcantly higher in patients
(23–81pg/mL) than controls ( <12.5– 73pg/mL) (P<. 001).
Serum levels of IL-12/p40 were determined in 11 of 20 AD
patients in the study group and in 8 of healthy individuals in
thecontrolgroup.Therewasnotastatisticallysigniﬁcantdif-
ference between patients (< 2–93pg/mL) and controls (< 2–
52pg/mL)inrespectofserumlevelsofIL-12/p40(P = .227).
Serum levels of IFN-γ could not be determined in any of the
patientsinthestudygrouporhealthyindividuals.Resultsare
shown in Table 1.
A statistically signiﬁcant relationship between serum lev-
els of total IgE (r = 0.99; P<. 001), IL-18 (r = 0.99;
P<. 001), IL-12/p40 (r = 0.84; P<. 001), and SCORADs
in children with AD was determined. Also, the relationship
between serum levels of total IgE and serum levels of IL-18
(r = 0.99; P<. 001) and IL-12/p40 (r = 0.85; P<. 001)
in patients with AD was determined to be statistically sig-
niﬁcant. The relationship between the disease severity and
serum levels of total IgE, IL-12/p40, IL-18 is presented in
Table 2.
DISCUSSION
Serum IgE level is often increased in allergic diseases. But a
normal serum IgE level does not mean that atopy does not
exist. On the other hand, very high serum IgE level can be
accepted as one of the important data showing allergy exis-
tence if there is no parasitic infestation [22]. Increased IgE
level, basophile and mast cell degranulations, and released
mediators are important for AD but these are secondary fea-
tures with cAMP function disorders. Although IgE has a role
on formation of allergic rhinitis and some forms of allergic
asthma, there are few publications in the literature that IgE
has a major role on the pathogenesis of AD. It is stated inMurat Aral et al 3
Table 1: Serum levels of total IgE, IL-18, and IL-12/p40 in control group and in patient group.
Groups Total IgE (IU/mL) IL-18 (pg/mL) IL-12 (pg/mL)
Patient group (n = 20) 275, (176–847) 68, (23–81) 31, (< 2–93)
Median, (minimum-maximum)
Control group (n = 19) 32, (18–81) < 12.5, (< 12.5–73) < 2, (< 2–52)
Median, (minimum-maximum)
P value P<. 001 P<. 001 P = .227
Table 2: Relationship between SCORAD values and serum levels of total IgE, IL-18, IL-12/p40.
SCORAD, total IgE, and cytokines Statistical values SCORAD Total IgE IL-18
Total IgE R .99 — —
P< . 001 — —
IL-18 R .99 .99 —
P< . 001 <. 001 —
IL-12/p40 R .84 .85 .85
P< . 001 <. 001 <. 001
the literature that serum IgE levels correlate with AD severity
[1, 23, 24]. Laske and Niggemann performed a retrospective
study on 345 child patients with AD and determined that
SCORAD values were statistically signiﬁcantly related with
serum IgE levels [25]. It was determined in our study that
serum total IgE levels were below 200IU/mL in only 4 of
20 patients with AD and they were statistically signiﬁcantly
higher in study group than in control group. Also a statisti-
cally signiﬁcant relationship was determined between SCO-
RAD values and serum total IgE levels.
IL-18 acts synergistically with IL-12 to stimulate the de-
velopment of Th1 cells in in vivo conditions. It has been
shown that IL-18 also increases Th2 cytokine production,
eosinophily, and allergic sensitivity in ragweed-antigen stim-
ulated models [26]. It induces IL-13 that is a Th2 cytokine
andmakesthisinductionsynergisticallywithIL-12innonex-
istence of IFN-γ [15]. It is determined that IL-13 is the major
determinant of serum IgE levels in patients with AD [6, 27].
It is shown in a study performed by Hoshino et al about
stimulation of Th2 response by IL-18 mediation that IL-18
induces IgE production independently from IL-4 in in vivo
conditions [16]. Shida et al found that serum IL-12/p40 lev-
els were higher in AD patients than in controls and there was
a relationship between serum IL-12/p40 levels [28]. These
researchers separated IL-18 functionally into type-1 (active)
and type-2 (inactive) and while they determined type-1 IL-
18 in all AD patients, they determined type-2 IL-18 only in
3 AD patients with low serum IgE levels. Because of this,
they put forward that type-2 IL-18 may be reciprocally re-
latedwithserumIgElevelsinthepatients.Theyfoundserum
IFN-γ levels below determination limits in all patients. It was
determined in a study performed by Yoshizawa et al that
there was no statistically signiﬁcant diﬀerence between AD
patients and controls in respect of serum IL-12 levels but
serum IL-18 levels were higher in AD patients than in con-
trols[29]. It is also determined in this study that serum IL-18
levels correlate with clinical activity of AD. It is determined
in a study performed on 19 child patients with AD that SCO-
RAD scores were statistically signiﬁcantly related with serum
IL-18 levels and serum IFN-γ levels could not be determined
in patients with AD and in controls [30].
We found in our study that serum IL-18 levels were sta-
tistically signiﬁcantly higher in AD patients than in control
group. On the other hand, we could not determine a statisti-
cally signiﬁcant diﬀerence between AD patients and healthy
controls in respect of serum IL-12/p40 levels. We found that
SCORAD values were statistically signiﬁcantly related with
serum levels of IL-18 and IL-12/p40. The relationship be-
tween serum total IgE levels and serum levels of IL-18 and
IL-12/p40 was also determined to be statistically signiﬁcant
in AD patients.
Serum levels of IFN-γ were determined below determi-
nation limit in both study group and control group. Serum
levels of IFN-γ and IL-12 increase in chronic phase lesions of
AD but they are measured at the same level with unaﬀected
skin in acute phase lesions of AD [31]. These two parame-
ters might be found in normal limits in this study because
of most of the patients in our study being in the acute phase
of AD. High serum IL-18 levels make us think that IL-18 is
a sensitive parameter that correlates with clinical severity of
AD and may play a role on immunopathogenesis of AD.
These results show that serum levels of IL-18 and IgE
may be used as important markers in the assessment of dis-
ease severity and follow-up of child patients with AD. We
believe that these kinds of studies will give clues on deter-
mining diagnosis, treatment, and protection strategies about
AD in the future. As a result, the role of cytokines and the
relationship between cytokines in the immunopathogenesis
of AD are rather complex and still not clearly clariﬁed. Espe-
cially,wheninvitroandinvivofunctionalvariationofIL-18,
the complexity of bioactivities triggered by IL-18 and inter-
actions between IL-18 and other cytokines are considered,
further investigations are required to understand this com-
plex process.4 Mediators of Inﬂammation
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